CD4 and breast cancer: Alisertib has been shown to alter the immunosuppressive state by eliminating MDSCs via apoptosis and to enhance antitumor immunity by increasing CD8+ and CD4+ T cell abundance, leading to the regression of mouse mammary tumors [136].